Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review

BACKGROUND: China’s National Reimbursement Drug List (NRDL) has become the primary route for drug reimbursement in China. More recently, the authority has made pharmacoeconomic evaluation an integral part of the application for NRDL inclusion. The underlying financial conflict of interests (FCOI) of...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Zixuan, Huang, Xianqin, Chen, Dingyi, Wang, Guoan, Zhu, Yuezhen, Li, Huangqianyu, Han, Sheng, Shi, Luwen, Guan, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689407/
https://www.ncbi.nlm.nih.gov/pubmed/38030227
http://dx.doi.org/10.1136/bmjgh-2023-012780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689407/
https://www.ncbi.nlm.nih.gov/pubmed/38030227
http://dx.doi.org/10.1136/bmjgh-2023-012780

Ejemplares similares